Q-omics provides the consensus-scored VHLL profile across patient tissues and cancer cell-line models. VHLL expression is associated with patient survival in 16 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, VHLL is differentially expressed in 7, with the highest sampling consensus in THCA. Additionally, VHLL RNA expression shows 9,985 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight KIRC, THCA, and UVM as cancer lineages where VHLL shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for VHLL — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes VHLL survival associations across molecular data types. VHLL RNA expression shows survival associations in the most cancer types (16), followed by mutation status (2). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible VHLL RNA expression–survival associations across cancer types. High VHLL expression shows unfavorable associations in KIRC, LIHC, UVM and SCLC, but favorable associations in LGG and UCS. The KIRC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for VHLL RNA expression.
This table summarizes VHLL tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 7. The strongest signals are observed in THCA for RNA.
This table ranks reproducible tumor–normal expression differences for VHLL. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. VHLL shows lower tumor expression in THCA and higher tumor expression in COAD, LIHC, LUSC, KIRC and READ. The THCA box plot shows higher VHLL RNA expression in normal versus tumor tissue (log2 FC = −0.113, t-test p < 0.001).
This table shows molecular features associated with VHLL in patient tissues and cancer cell lines. In patient samples, VHLL shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set. In cancer cell lines, VHLL RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BLOOD_Leukemia, while CRISPR and shRNA rows add functional-dependency signals in OVARY.
